Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP977724.RAQNPDC-hppGl2xglRr_eFciRuSxVKWtHTdZvm8VKfEI4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP977724.RAQNPDC-hppGl2xglRr_eFciRuSxVKWtHTdZvm8VKfEI4130_assertion type Assertion NP977724.RAQNPDC-hppGl2xglRr_eFciRuSxVKWtHTdZvm8VKfEI4130_head.
- NP977724.RAQNPDC-hppGl2xglRr_eFciRuSxVKWtHTdZvm8VKfEI4130_assertion description "[Because pretargeting strategies yield high signal-to-background ratios, we evaluated the feasibility of a pretargeting strategy for intraoperative imaging in prostate cancer using an anti-TROP-2 x anti-HSG bispecific antibody (TF12) in conjunction with the dual-labeled diHSG peptide (RDC018) equipped with both a DOTA chelate for radiolabeling purposes and a fluorophore (IRdye800CW) to allow near-infrared optical imaging.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP977724.RAQNPDC-hppGl2xglRr_eFciRuSxVKWtHTdZvm8VKfEI4130_provenance.
- NP977724.RAQNPDC-hppGl2xglRr_eFciRuSxVKWtHTdZvm8VKfEI4130_assertion evidence source_evidence_literature NP977724.RAQNPDC-hppGl2xglRr_eFciRuSxVKWtHTdZvm8VKfEI4130_provenance.
- NP977724.RAQNPDC-hppGl2xglRr_eFciRuSxVKWtHTdZvm8VKfEI4130_assertion SIO_000772 25252911 NP977724.RAQNPDC-hppGl2xglRr_eFciRuSxVKWtHTdZvm8VKfEI4130_provenance.
- NP977724.RAQNPDC-hppGl2xglRr_eFciRuSxVKWtHTdZvm8VKfEI4130_assertion wasDerivedFrom befree-20150227 NP977724.RAQNPDC-hppGl2xglRr_eFciRuSxVKWtHTdZvm8VKfEI4130_provenance.
- NP977724.RAQNPDC-hppGl2xglRr_eFciRuSxVKWtHTdZvm8VKfEI4130_assertion wasGeneratedBy ECO_0000203 NP977724.RAQNPDC-hppGl2xglRr_eFciRuSxVKWtHTdZvm8VKfEI4130_provenance.